RDRegina Durón

Regina Durón

*This is an algorithmically generated author record based on publicly available information.

Regina Durón has a total of 10 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Lecciones aprendidas en la implementación de campañas de vacunación contra el sarampión y la rubéola en las Américas

    by Regina Durón, Desirée Pastor, Álvaro Whittembury, Daniele Rocha Queiroz Lemos

    To systematize and share knowledge and lessons learned from the implementation of follow-up vaccination campaigns in the Region of the Americas between 2003 and 2023. Descriptive report with a quantitative and qualitative analysis of the achievement of targets and lessons learned in 20 years of follow-up vaccination campaigns. The sources consulted were joint reports to WHO and the United Nations Children's Fund on vaccination data and reports to the Regional Commission for Monitoring and Re-Verification of the Elimination of Measles, Rubella and Congenital Rubella Syndrome. During the period from 2003 to 2023, 68 follow-up campaigns were implemented in 20 countries in the Region of the Americas. Of these, 50.0% (34/68) achieved the minimum expected target of ≥ 95%. In the first decade, from 2003 to 2012, 49.0% (33/68) of the follow-up campaigns were implemented; of those, 54.5% (18/33) achieved ≥ 95%. In the second decade, from 2013 to 2023, 51.0% (35/68) were implemented, with 45.7% (16/35) reaching the ≥ 95% target. The COVID-19 pandemic negatively impacted achievement of the targets in the second decade. During the COVID-19 pandemic, 12 follow-up campaigns were carried out; of these, 58.3% (7/12) did not reach at least 95% of the target population. Follow-up vaccination campaigns are a fundamental tool for sustaining measles and rubella elimination in the Americas, making it possible to update children's immunization schedules and strengthen the routine program.


  • Open Access

    Sustaining the Elimination of Measles, Rubella and Congenital Rubella Syndrome in the Americas, 2019–2023: From Challenges to Opportunities

    by Gloria Rey-Benito, Desirée Pastor, Alvaro Whittembury, Regina Durón, Carmelita Pacis-Tirso, Pamela Bravo-Alcántara, Claudia Ortiz, Jon Andrus

    This report reviews national data from all Member States on measles, rubella, and congenital rubella syndrome (CRS) elimination in the Region of the Americas during 2019–2023. It includes an analysis of compliance with vaccination coverage, surveillance indicators, and measles outbreaks, as well as an analysis of the response capacity of the laboratory network and a country case study that meets all indicators. The sources of information were the integrated epidemiological surveillance system for measles and rubella of the Pan American Health Organization (PAHO)/World Health Organization (WHO) and the Joint Reporting Form (eJRF), among others. From 2020 to 2022, regional coverage with first (MMR-1) and second doses (MMR-2) decreased to rates below 90%. The regional suspected case notification rate was maintained above the minimum expected 2.0 suspect cases per 100,000 population, except in 2021. During 2019 to 2023, 18 countries experienced outbreaks, with two of the outbreaks resulting in re-established endemic transmission. In conclusion, two countries in the Americas have not maintained measles elimination, but by the end of 2023 no country showed endemic measles transmission. One of the countries that lost its certification of elimination in 2018 managed to be reverified in 2023; the other is pending reverification. All countries maintained rubella elimination. Despite these challenges, the sustainability of the elimination of these diseases remains a health priority in the Region.